Post-IPO Equity - Mycenax Biotech
Investment Firm
Overview
Mycenax Biotech is a biologics CDMO company developing recombinant proteins, enzymes, antibodies, antibody-drug conjugates.
Announced Date
Jul 27, 2022
Funding Type
Post Ipo Equity
Highlights
Location
Asia
Social
Investor Lead
Participant Investors
1
| Investor Name |
|---|
 JCR Pharmaceuticals |
Round Details and Background
Mycenax Biotech raised $56000000 on 2022-07-27 in Post-IPO Equity
Mycenax Biotech is a biologics CDMO company developing recombinant proteins, enzymes, antibodies, antibody-drug conjugates.
Company Funding History
1
| Announcment Date | Transaction Name | Number Of Investors | Lead Investor | Money Raised |
|---|---|---|---|---|
| Jul 27, 2022 |  Post-IPO Equity - Mycenax Biotech | 1 | - | 56.0M |
Recent Activity
There is no recent news or activity for this profile.